Article
Immune reactivity to Trypanosoma cruzi chimeric proteins for Chagas disease diagnosis in immigrants living in a non-endemic setting
Registro en:
DOPICO, Eva et al. Immune reactivity to Trypanosoma cruzi chimeric proteins for Chagas disease diagnosis in immigrants living in a non-endemic setting. BMC Infectious Diseases, v. 19, p. 1-7, 2019.
1471-2334
10.1186/s12879-019-3872-z
Autor
Dopico, Eva
Del-Rei, Rodrigo Pimenta
Espinoza, Bertha
Ubillos, Itziar
Zanchin, Nilson Ivo Tonin
Sulleiro, Elena
Moure, Zaira
Celedon, Paola Alejandra Fiorani
Souza, Wayner Vieira
Silva, Edimilson Domingos da
Gomes, Yara Miranda
Santos, Fred Luciano Neves
Resumen
This research project was funded by a Gonçalo Moniz Institute, Oswaldo
Cruz Foundation (Fiocruz/BA). Chronic Chagas Disease (CD) diagnosis is based on serological methods employing crude, semipurified or recombinant antigens, which may result in low sensitivity or cross-reactivity. To reduce these restrictions, we developed a strategy involving use of molecules containing repetitive fragments of Trypanosoma cruzi conserved proteins. Diagnostic performance of IBMP-8.1 and IBMP-8.4 chimeric antigens (Molecular Biology Institute of Paraná - IBMP in Portuguese acronym) was assessed to diagnose T. cruzi-infected and non-infected immigrants living in Barcelona (Spain), a non-endemic setting for Chagas disease. Methods: Reactivity of IBMP-8.1 and IBMP-8.4 was assessed using an in-house automated ELISA with 347 positive
and 331 negative individuals to Chagas disease. Antigenic cross-reactivity was measured with sera samples from
pregnant women with Toxoplasma gondii (n = 98) and Zika virus (n = 75) antibodies.
Results: The area under the curve values was 1 and 0.99 for the IBMP-8.1 and IBMP-8.4 proteins, respectively,
demonstrating excellent diagnostic accuracy. The reactivity index was higher for IBMP-8.1 than IBMP-8.4 in positive
samples and no significant difference in reactivity index was observed in negative samples. Sensitivity ranged from
99.4% for IBMP-8.1 to 99.1% for IBMP-8.4 and was not statistically different. Specificity for IBMP-8.1 reached 100 and
99.7% for IBMP-8.4, both nearly 100% accurate. No antigenic cross-reactivity was observed and reactivity index was
similar to that for negative Chagas disease individuals.
Conclusions: Our results showed an outstanding performance of IBMP-8.1 and IBMP-8.4 chimeric antigens by ELISA
and suggest both chimeric antigens could also be used for Chagas disease diagnosis in immigrants living in nonendemic
settings.